Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans Cell Histiocytosis.

Sagna Y, Courtillot C, Drabo JY, Tazi A, Donadieu J, Idbaih A, Cohen F, Amoura Z, Haroche J, Touraine P.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-19-0177.R2. doi: 10.1530/EJE-19-0177. [Epub ahead of print]

PMID:
31269469
2.

Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A.

J Neurooncol. 2019 Jun 13. doi: 10.1007/s11060-019-03204-0. [Epub ahead of print]

PMID:
31197598
3.

Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.

Nowosielski M, Gorlia T, Bromberg JEC, Sahm F, Harting I, Kickingereder P, Brandes AA, Taphoorn MJB, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Weller M, Fabbro M, Le Rhun E, Platten M, Golfinopoulos V, van den Bent MJ, Bendszus M, Wick W.

Neurology. 2019 Jun 11;92(24):e2754-e2763. doi: 10.1212/WNL.0000000000007643. Epub 2019 May 10.

PMID:
31076534
4.

Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.

PMID:
30890548
5.

Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure.

Asquier N, Bouchoux G, Canney M, Martin C, Law-Ye B, Leclercq D, Chapelon JY, Lafon C, Idbaih A, Carpentier A.

J Neurosurg. 2019 Feb 1:1-9. doi: 10.3171/2018.9.JNS182001. [Epub ahead of print]

PMID:
30717050
6.

Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit.

Decavèle M, Rivals I, Marois C, Cantier M, Weiss N, Lemasle L, Prodanovic H, Hoang-Xuan K, Idbaih A, Similowski T, Demoule A.

J Neurooncol. 2019 Mar;142(1):139-148. doi: 10.1007/s11060-018-03074-y. Epub 2018 Dec 7.

PMID:
30536197
7.

Neuro-oncology: A rapidly evolving multidisciplinary speciality.

Idbaih A, Delattre JY.

Presse Med. 2018 Nov - Dec;47(11-12 Pt 2):e185-e186. doi: 10.1016/j.lpm.2018.11.016. No abstract available.

PMID:
30502027
8.

CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.

Di Stefano AL, Savatovsky J, Feuvret L, Villa C, Reina V, Pha M, Houillier C, Berzero G, Idbaih A, Psimaras D.

Neuro Oncol. 2019 Jan 1;21(1):139-141. doi: 10.1093/neuonc/noy168. No abstract available.

PMID:
30476174
9.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Héritier S, Barkaoui MA, Miron J, Thomas C, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Jeziorski E, Plat G, Aladjidi N, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Pagnier A, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Gandemer V, Martin-Duverneuil N, Taly V, Hélias-Rodzewicz Z, Emile JF, Hoang-Xuan K, Idbaih A, Donadieu J.

Br J Haematol. 2018 Nov;183(4):608-617. doi: 10.1111/bjh.15577. Epub 2018 Nov 12.

PMID:
30421536
10.

Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.

Hottinger AF, Bensaid D, De Micheli R, Moura B, Mokhtari K, Cardoso E, Idbaih A, Stupp R.

Ann Oncol. 2019 Jan 1;30(1):155-156. doi: 10.1093/annonc/mdy468. No abstract available.

PMID:
30346479
11.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

12.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
13.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
14.

Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.

Morisse MC, Jouannet S, Dominguez-Villar M, Sanson M, Idbaih A.

Expert Rev Neurother. 2018 Sep;18(9):729-737. doi: 10.1080/14737175.2018.1510321. Epub 2018 Aug 22. Review.

PMID:
30099909
15.

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17.

PMID:
30018130
16.

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM.

Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.

17.

FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.

PMID:
29728520
18.

Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.

PMID:
29549621
19.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

20.

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.

PMID:
29520610
21.

Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

Fontanilles M, Duran-Peña A, Idbaih A.

Curr Neurol Neurosci Rep. 2018 Mar 9;18(3):13. doi: 10.1007/s11910-018-0820-z. Review.

PMID:
29520561
22.

Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.

Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19.

23.

Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort.

Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, Cluzel P, Donadieu J, Idbaih A, Barete S, Amoura Z, Haroche J.

Am J Hematol. 2018 May;93(5):E114-E117. doi: 10.1002/ajh.25055. Epub 2018 Feb 10. No abstract available.

24.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

25.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

26.

Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma.

Le Fèvre R, Durand-Dubief M, Chebbi I, Mandawala C, Lagroix F, Valet JP, Idbaih A, Adam C, Delattre JY, Schmitt C, Maake C, Guyot F, Alphandéry E.

Theranostics. 2017 Oct 13;7(18):4618-4631. doi: 10.7150/thno.18927. eCollection 2017.

27.

Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness.

Bogeas A, Morvan-Dubois G, El-Habr EA, Lejeune FX, Defrance M, Narayanan A, Kuranda K, Burel-Vandenbos F, Sayd S, Delaunay V, Dubois LG, Parrinello H, Rialle S, Fabrega S, Idbaih A, Haiech J, Bièche I, Virolle T, Goodhardt M, Chneiweiss H, Junier MP.

Acta Neuropathol. 2018 Feb;135(2):267-283. doi: 10.1007/s00401-017-1783-x. Epub 2017 Nov 17.

28.

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.

PMID:
29143276
29.

Lomustine and Bevacizumab in Progressive Glioblastoma.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ.

N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

30.

Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience.

Decavèle M, Weiss N, Rivals I, Prodanovic H, Idbaih A, Mayaux J, Similowski T, Demoule A.

J Neurol. 2017 Nov;264(11):2303-2312. doi: 10.1007/s00415-017-8624-7. Epub 2017 Oct 9.

PMID:
28993874
31.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

32.

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco.

Senhaji N, Louati S, Chbani L, El Fatemi H, Hammas N, Mikou K, Maaroufi M, Benzagmout M, Boujraf S, El Bardai S, Giry M, Marie Y, Chaoui El Faiz M, Mokhtari K, Idbaih A, Amarti A, Bennis S.

Biomed Res Int. 2017;2017:8045859. doi: 10.1155/2017/8045859. Epub 2017 Jul 13.

33.

Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

J Control Release. 2017 Sep 28;262:259-272. doi: 10.1016/j.jconrel.2017.07.020. Epub 2017 Jul 13.

PMID:
28713041
34.

Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

Biomaterials. 2017 Oct;141:210-222. doi: 10.1016/j.biomaterials.2017.06.026. Epub 2017 Jun 21.

PMID:
28689117
35.

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J, Maksud P, Idbaih A, Barete S, Hoang-Xuan K, Amoura Z, Haroche J.

Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30. No abstract available.

36.

Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing.

Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau M, Schmitt C, Masliah-Planchon J, Bourdeaut F, Dehais C, Marie Y, Delattre JY, Idbaih A.

Acta Neuropathol. 2017 Nov;134(5):691-703. doi: 10.1007/s00401-017-1743-5. Epub 2017 Jun 21.

37.

Structural and functional intratumor heterogeneities in glioblastoma: a spacetime odyssey at single-cell level.

Idbaih A.

Ann Oncol. 2017 Jul 1;28(7):1415-1417. doi: 10.1093/annonc/mdx217. No abstract available.

PMID:
28472456
38.

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussière M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nöthen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M; GliomaScan Consortium, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML.

Nat Genet. 2017 May;49(5):789-794. doi: 10.1038/ng.3823. Epub 2017 Mar 27.

39.

Histiocytoses: emerging neoplasia behind inflammation.

Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, Vaglio A, Abdel-Wahab O, Emile JF, Amoura Z.

Lancet Oncol. 2017 Feb;18(2):e113-e125. doi: 10.1016/S1470-2045(17)30031-1. Review.

PMID:
28214412
40.

Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.

Ollier E, Mazzocco P, Ricard D, Kaloshi G, Idbaih A, Alentorn A, Psimaras D, Honnorat J, Delattre JY, Grenier E, Ducray F, Samson A.

Fundam Clin Pharmacol. 2017 Jun;31(3):347-358. doi: 10.1111/fcp.12259. Epub 2017 Jan 24.

PMID:
27933657
41.

[Neuro-Langerhans cell histiocytosis].

Le Guennec L, Martin-Duverneuil N, Mokhtari K, Santiago-Ribeiro M, Bayen E, Del Cul A, Delgadillo D, Kas A, Courtillot C, Haroche J, Cohen F, Donadieu J, Hoang-Xuan K, Idbaih A.

Presse Med. 2017 Jan;46(1):79-84. doi: 10.1016/j.lpm.2016.09.014. Epub 2016 Nov 2. Review. French.

PMID:
27816346
42.

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.

Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR.

Nat Biotechnol. 2016 Nov;34(11):1161-1167. doi: 10.1038/nbt.3697. Epub 2016 Oct 10.

43.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, Chanut A, Polivka M, Poggioli S, Rosenberg S, Giry M, Marie Y, Duyckaerts C, Sanson M, Figarella-Branger D, Idbaih A; Pola Network.

Brain Pathol. 2017 Sep;27(5):567-579. doi: 10.1111/bpa.12434. Epub 2016 Oct 28.

PMID:
27543943
44.

Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma.

Le Guennec L, Maisonobe T, Choquet S, Massein A, Azoulay-Cayla A, Villain N, Archambaud F, Hoang-Xuan K, Idbaih A.

Leuk Lymphoma. 2017 Mar;58(3):729-731. doi: 10.1080/10428194.2016.1211277. Epub 2016 Aug 9. No abstract available.

PMID:
27686620
45.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
46.

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2017 Feb 1;19(2):219-228. doi: 10.1093/neuonc/now160.

47.

Radiation plus Chemotherapy in Low-Grade Glioma.

Touat M, Idbaih A, Sanson M.

N Engl J Med. 2016 Aug 4;375(5):489-90. doi: 10.1056/NEJMc1605897. No abstract available.

PMID:
27518678
48.

Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Labussière M, Rahimian A, Giry M, Boisselier B, Schmitt Y, Polivka M, Mokhtari K, Delattre JY, Idbaih A, Labreche K, Alentorn A, Sanson M.

Oncologist. 2016 Sep;21(9):1131-5. doi: 10.1634/theoncologist.2016-0003. Epub 2016 Jul 8.

49.

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.

Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, Idbaih A.

Expert Rev Neurother. 2016 Nov;16(11):1285-1300. Epub 2016 Jul 4. Review. Erratum in: Expert Rev Neurother. 2016 Nov;16(11):iv.

PMID:
27310463
50.

Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A.

Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086.

PMID:
27306666

Supplemental Content

Loading ...
Support Center